Ophthalmic Therapeutic Innovation has raised $250K in pre-seed funding. The company is working on treatments for glaucoma, aiming to do more than slow the disease - it wants to improve patients' quality of life along the way.
OTI says its approach combines research, patient insights, and clinical expertise, with the goal of delivering therapies that offer new hope and clearer vision to people affected by the condition. The startup also emphasizes transparency and ethical practice as part of its stated mission. The pre-seed round gives OTI its first outside capital as it works to move that research forward.
